Zai Lab, Innoviva: China Oks XACDURO For Hospital-Acquired, Ventilator-Associated Pneumonia In 18+

Zai Lab Ltd. (ZLAB) and Innoviva Specialty Therapeutics announced Monday that China's National Medical Products Administration or NMPA has approved Zai Lab's New Drug Application for XACDURO (sulbactam-durlobactam) to treat hospital-acquired and ventilator-associated pneumonia caused by Acinetobacter baumannii-calcoaceticus complex in China.

Related Keywords

China ,Chinese ,Harald Reinhart ,Entasis Therapeutics Inc ,China National Medical Products Administration ,Head Of Global Development ,Zai Lab ,Zai Lab New Drug Application ,Drug Administration ,Zai Lab Ltd ,More Such Health News ,World Health Organization ,Innoviva Specialty Therapeutics ,National Medical Products Administration ,New Drug Application ,Greater China ,Global Development ,Infectious Diseases ,